Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study

Robin Schaefer, Heather-Marie A Schmidt, Giovanni Ravasi, Antons Mozalevskis, Bharat B Rewari, Frank Lule, Kouadio Yeboue, Anne Brink, Nabeel Mangadan Konath, Mukta Sharma, Nicole Seguy, Joumana Hermez, Ahmed S Alaama, Naoko Ishikawa, Boniface Dongmo Nguimfack, Daniel Low-Beer, Rachel Baggaley, Shona Dalal, Robin Schaefer, Heather-Marie A Schmidt, Giovanni Ravasi, Antons Mozalevskis, Bharat B Rewari, Frank Lule, Kouadio Yeboue, Anne Brink, Nabeel Mangadan Konath, Mukta Sharma, Nicole Seguy, Joumana Hermez, Ahmed S Alaama, Naoko Ishikawa, Boniface Dongmo Nguimfack, Daniel Low-Beer, Rachel Baggaley, Shona Dalal

Abstract

Background: In 2016, the UN General Assembly set a global target of 3 million oral pre-exposure prophylaxis (PrEP) users by 2020. With this target at an end, we aimed to assess global trends in the adoption of WHO PrEP recommendations into national guidelines and numbers of PrEP users, defined as people who received oral PrEP at least once in a given year, and to estimate future trajectories of PrEP use.

Methods: In this global summary and forecasting study, data on adoption of WHO PrEP recommendations and numbers of PrEP users were obtained through the Global AIDS Monitoring system and WHO regional offices. Trends in these indicators for 2016-19 by region and for 2019 by country were described, including by gender and priority populations where data were available. PrEP user numbers were forecasted until 2023 by selecting countries with at least 3 years of PrEP user data as example countries in each region to represent possible future PrEP user trajectories. PrEP user growth rates observed in example countries were applied to countries in corresponding regions under different scenarios, including a COVID-19 disruption scenario with static global PrEP use in 2020.

Findings: By the end of 2019, 120 (67%) of 180 countries with data had adopted the WHO PrEP recommendations into national guidelines (23 in 2019 and 30 in 2018). In 2019, there were about 626 000 PrEP users across 77 countries, including 260 000 (41·6%) in the region of the Americas and 213 000 (34·0%) in the African region; this is a 69% increase from about 370 000 PrEP users across 66 countries in 2018. Without COVID-19 disruptions, 0·9-1·1 million global PrEP users were projected by the end of 2020 and 2·4-5·3 million are projected by the end of 2023. If COVID-19 disruptions resulted in no PrEP user growth in 2020, the projected number of PrEP users in 2023 is 2·1-3·0 million.

Interpretation: Widespread adoption of WHO PrEP recommendations coincided with a global increase in PrEP use. Although the 2020 global PrEP target will be missed, strong future growth in PrEP use is possible. New PrEP products could expand the PrEP user base, and, with greater expansion of oral PrEP, further adoption of WHO PrEP recommendations, and simplified delivery, PrEP could contribute to ending AIDS by 2030.

Funding: Unitaid, Bill & Melinda Gates Foundation, and WHO.

Conflict of interest statement

Declaration of interests We declare no competing interests.

Copyright © 2021 World Health Organization; licensee Elsevier. This is an Open Access article published under the CC BY 3.0 IGO license which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In any use of this article, there should be no suggestion that WHO endorses any specific organisation, products or services. The use of the WHO logo is not permitted. This notice should be preserved along with the article's original URL.

Figures

Figure 1
Figure 1
Adoption of the WHO recommendations on oral PrEP into national guidelines globally by 2019 Pending adoption was defined as plans to adopt the recommendation in the next 2 calendar years. Estimates were based on data from the Global AIDS Monitoring system and reporting to WHO. See the appendix (pp 1–7) for details on data. PrEP=pre-exposure prophylaxis.
Figure 2
Figure 2
Numbers of countries that have adopted the WHO recommendations on oral PrEP into national guidelines per year by WHO region The figure includes countries that are yet to implement these guidelines. Pending adoption was defined as plans to adopt the recommendation in the next 2 calendar years. Estimates were based on the Global AIDS Monitoring system and reporting to WHO. See the appendix (pp 1–7) for details on data. Regions refer to WHO regional offices. AFRO=African region. EMRO=Eastern Mediterranean region. EURO=European region. PAHO=region of the Americas. PrEP=pre-exposure prophylaxis. SEARO=South-East Asia region. WPRO=Western Pacific region.
Figure 3
Figure 3
Numbers of people who have received oral PrEP at least once (PrEP users) globally in 2019 Estimates were based on data from the Global AIDS Monitoring system and reporting to WHO. See the appendix (pp 1–7) for details on data. PrEP=pre-exposure prophylaxis.
Figure 4
Figure 4
Numbers of people who received oral PrEP at least once (PrEP users) per year by WHO region Data for 2012–15 were added for illustration of longer-term trends and were taken from Sullivan and colleagues, which were limited to the USA. Estimates for 2016–19 were based on the Global AIDS Monitoring system and reporting to WHO. See the appendix (pp 1–7) for details on data. Regions refer to WHO regional offices. AFRO=African region. EMRO=Eastern Mediterranean region. EURO=European region. PAHO=region of the Americas. PrEP=pre-exposure prophylaxis. SEARO=South-East Asia region. WPRO=Western Pacific region.
Figure 5
Figure 5
Forecasted global numbers of PrEP users per year until 2023 PrEP users were defined as people who have received oral PrEP at least once. (A) Without COVID-19 disruptions, projections based on three observed example trajectories for each region applied to all countries in the region; lower growth was based on the example trajectories with 25% lower growth at each time step; countries that had adopted the WHO PrEP recommendations or were pending the adoption were assumed to introduce PrEP services in 2020; in the linear growth scenario, the same number of PrEP users was added to each country as observed between the past 2 years of data availability and no country was assumed to introduce PrEP services. (B) Forecasted PrEP users by WHO region without assumed COVID-19 disruptions in 2023; vertical lines represent the average growth scenarios (upper limit) and 25%-reduced growth scenarios (lower limit); diamonds represent 2019 PrEP user numbers. (C) The modelled COVID-19 disruption scenario assumed no growth in 2020 and PrEP seeding in countries was postponed until 2021. After the disruption, growth in PrEP users was modelled with the same trajectories as without COVID-19 disruptions. AFRO=African region. EMRO=Eastern Mediterranean region. EURO=European region. PAHO=region of the Americas. PrEP=pre-exposure prophylaxis. SEARO=South-East Asia region. WPRO=Western Pacific region.

References

    1. Chou R, Evans C, Hoverman A. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2019;321:2214–2230.
    1. Holmes D. FDA paves the way for pre-exposure HIV prophylaxis. Lancet. 2012;380:325.
    1. WHO Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach, 2nd edn. 2016.
    1. WHO What's the 2+1+1? Event-driven oral pre-exposure prophylaxis to prevent HIV for men who have sex with men. 2019.
    1. WHO WHO recommends the dapivirine vaginal ring as a new choice for HIV prevention for women at substantial risk of HIV infection. Jan 26, 2021.
    1. Landovitz R, Donnell D, Clement M, et al. HPTN083 interim results: pre-exposure prophylaxis (PrEP) containing long-acting injectable cabotegravir (CAB-LA) is safe and highly effective for cisgender men and transgender women who have sex with men (MSM, TGW). 23rd International AIDS Conference; virtual; July 6–10, 2020 (abstr 10750).
    1. WHO Trial results reveal that long-acting injectable cabotegravir as PrEP is highly effective in preventing HIV acquisition in women. Nov 9, 2020.
    1. United Nations General Assembly Political declaration on HIV and AIDS: on the fast track to accelerating the fight against HIV and to ending the AIDS epidemic by 2030. June 8, 2016.
    1. The Lancet HIV Are 2 million bottles of PrEP an empty gesture? Lancet HIV. 2019;6:e483.
    1. Sullivan PS, Giler RM, Mouhanna F. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infection, United States, 2012–2017. Ann Epidemiol. 2018;28:833–840.
    1. Brisson J. Ethical public health issues for the use of informal PrEP. Glob Public Health. 2018;13:1382–1387.
    1. Gilead Sciences China National Medical Products Administration approves Truvada® for HIV pre-exposure prophylaxis (PrEP) Aug 11, 2020.
    1. WHO Global Health Observatory data repository: number of people (all ages) living with HIV. Estimates by country. 2020.
    1. WHO Expanding contraceptive choice. Evidence brief. 2017.
    1. Funders Concerned About AIDS Philanthropic support to address HIV/AIDS in 2019. 2021.
    1. Torres TS, Hoagland B, Bezerra DRB. Impact of COVID-19 pandemic on sexual minority populations in Brazil: an analysis of social/racial disparities in maintaining social distancing and a description of sexual behavior. AIDS Behav. 2021;25:73–84.
    1. Davey DLJ, Bekker L-G, Mashele N, Gorbach P, Coates TJ, Myer L. PrEP retention and prescriptions for pregnant women during COVID-19 lockdown in South Africa. Lancet HIV. 2020;7:e735.
    1. Hammoud MA, Grulich A, Holt M. Substantial decline in use of HIV pre-exposure prophylaxis (PrEP) following introduction of COVID-19 physical distancing restrictions in Australia: results from a prospective observational study of gay and bisexual men. JAIDS J Acquir Immune Defic Syndr. 2021;86:22–30.
    1. Krakower D, Solleveld P, Levine K, Mayer K. Impact of COVID-19 on HIV preexposure prophylaxis care at a Boston community health center. 23rd International AIDS Conference; virtual; July 6–10, 2020 (abstr OACLB0104).
    1. WHO Disruption in HIV, hepatitis and STI services due to COVID-19: presentation with latest results as of July 8, 2020. 2020.
    1. Brawley S, Dinger J, Nguyen C, Anderson J. Impact of COVID-19 related shelter-in-place orders on PrEP access, usage and HIV risk behaviors in the United States. 23rd International AIDS Conference; virtual; July 6–10, 2020 (abstr OADLB0101).
    1. Phanuphak N, Sungsing T, Jantarapakde J. Princess PrEP program: the first key population-led model to deliver pre-exposure prophylaxis to key populations by key populations in Thailand. Sex Health. 2018;15:542–555.
    1. Celum CL, Delany-Moretlwe S, Baeten JM. HIV pre-exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to delivery. J Int AIDS Soc. 2019;22(suppl 4)
    1. Eakle R, Gomez GB, Naicker N. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: results from a prospective observational demonstration project. PLoS Med. 2017;14
    1. Mistler CB, Copenhaver MM, Shrestha R. The pre-exposure prophylaxis (PrEP) care cascade in people who inject drugs: a systematic review. AIDS Behav. 2021;25:1490–1506.
    1. Gomez GB, Borquez A, Case KK, Wheelock A, Vassall A, Hankins C. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med. 2013;10
    1. Grulich AE, Guy R, Amin J. Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study. Lancet HIV. 2018;5:e629–e637.
    1. Nwokolo N, Hill A, McOwan A, Pozniak A. Rapidly declining HIV infection in MSM in central London. Lancet HIV. 2017;4:e482–e483.
    1. Pretorius C, Schnure M, Dent J. Modelling impact and cost-effectiveness of oral pre-exposure prophylaxis in 13 low-resource countries. J Int AIDS Soc. 2020;23
    1. UNAIDS Seizing the moment. Tackling entrenched inequalities to end epidemics. 2020.
    1. Mansoor LE, Yende-Zuma N, Baxter C. Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. J Int AIDS Soc. 2019;22
    1. Beesham I, Welch JD, Heffron R. Integrating oral PrEP delivery among African women in a large HIV endpoint-driven clinical trial. J Int AIDS Soc. 2020;23

Source: PubMed

3
Sottoscrivi